Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic drug rule

This article was originally published in The Tan Sheet

Executive Summary

FDA's proposed rule to modify Hatch/Waxman patent procedures should be finalized this spring, Commissioner Mark McClellan, MD/PhD, said during a March 6 House Appropriations Subcommittee hearing on FDA's budget. President Bush announced the rule in October (1"The Tan Sheet" Oct. 28, 2002, p. 10)...

You may also be interested in...



Hatch/Waxman Reinterpretation Underpins Change In 30-Month Stay Policy

FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Hatch/Waxman language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification

Warning Letter Roundup & Recap – 27 February 2020

In separate warning letters, the US FDA says Biomedix (a maker of I.V. administration sets) and Unetixs Vascular (a maker of vascular diagnostic ultrasound systems) must hire outside consultants to review their quality systems after serious deficiencies were noted by agency investigators. A total of three enforcement missives were released by the FDA this week.

Xarelto And Eylea Keep Bayer Buoyant

The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.

Topics

UsernamePublicRestriction

Register

PS095218

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel